V
ZVRA icon

Veritable’s Zevra Therapeutics ZVRA Stock Holding History

Veritable’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$93K – 932
2021
Q3 		$93K Hold
10,000
– – ﹤0.01% 863
2021
Q2 		$128K Hold
10,000
– – ﹤0.01% 849
2021
Q1 		$92K Buy
+10,000
New +$87.3K ﹤0.01% 823

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
KA
Kovack Advisors Ft. Lauderdale, Florida $2.08B AUM 38.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Veritable's ZVRA Position: Q4 2021 in Review

Veritable sold out of Zevra Therapeutics (ZVRA) in Q4 2021, closing a stake of 10,000 shares — an estimated $93K sold.

Veritable first reported a position in ZVRA in Q1 2021 and held it in 3 quarters. The position peaked at $128K in Q2 2021. 77 funds tracked by Wall St. Rank hold ZVRA as of Q4 2021.

  • Veritable reported no remaining Zevra Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Veritable sold 10,000 Zevra Therapeutics shares in Q4 2021, an estimated $93K.
  • Veritable first reported a position in Zevra Therapeutics in Q1 2021 and held it in 3 quarters.
  • Veritable's Zevra Therapeutics position peaked at $128K in Q2 2021.
  • 77 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2021.

Based on Veritable's 13F filing for Q4 2021, filed 14 Feb 2022.